Click here to preview the new Fast Company

Want to try out the new FastCompany.com?

If you’d like to return to the previous design, click the yellow button on the lower left corner.

Update

Take Two

From big molecules spring big deals: Drugmaker Wyeth, which develops large-molecule pharmaceuticals cultivated from living cells ("Grand Experiment," February), is set to be acquired by Pfizer in a $68 billion megamerger. The move, announced in January, helps Pfizer fill holes in its R&D pipeline and could soften the impact of looming patent expiration of several of its blockbuster drugs. One nasty side effect: about 19,500 jobs lost from the combined company over the next three years.

Add New Comment

5 Comments